BTIG Research Reiterates Buy Rating for Adaptive Biotechnologies (NASDAQ:ADPT)

Key Points

• BTIG Research reiterated a "Buy" on Adaptive Biotechnologies with a $22 price target, implying roughly a 59.7% upside, and MarketBeat shows a consensus "Moderate Buy" with an average target of $19.43.
• Adaptive beat Q1 estimates with EPS of -$0.13 (vs. -$0.16 est.) and revenue of $70.9M (vs. $61.0M est.), up 35.1% year‑over‑year, but remains unprofitable with negative net margin and ROE.
• Insiders sold about 2.42M shares (~$34.2M) last quarter, while the stock opened at $13.78 (down ~5%), valuing the company at roughly $2.2B with a 12‑month range of $8.38–$20.76.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price target on the stock. BTIG Research's price objective would indicate a potential upside of 59.65% from the stock's previous close.

ADPT has been the subject of a number of other research reports. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research report on Saturday, March 7th. Guggenheim increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. TD Cowen reiterated a "buy" rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $19.43.

Adaptive Biotechnologies Stock Down 5.0%

Shares of NASDAQ:ADPT opened at $13.78 on Wednesday. The firm has a market capitalization of $2.20 billion, a PE ratio of -34.45 and a beta of 2.16. Adaptive Biotechnologies has a twelve month low of $8.38 and a twelve month high of $20.76. The company has a 50-day moving average price of $14.32 and a two-hundred day moving average price of $15.92.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company's quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.20) earnings per share. Analysts anticipate that Adaptive Biotechnologies will post -0.5 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, COO Julie Rubinstein sold 19,037 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $14.23, for a total transaction of $270,896.51. Following the completion of the sale, the chief operating officer directly owned 377,802 shares in the company, valued at $5,376,122.46. The trade was a 4.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 37,263 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $15.19, for a total transaction of $566,024.97. Following the sale, the chief executive officer owned 2,180,518 shares of the company's stock, valued at approximately $33,122,068.42. The trade was a 1.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 2,417,168 shares of company stock valued at $34,153,000. 5.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $28,000. EverSource Wealth Advisors LLC raised its stake in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. raised its stake in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after acquiring an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $51,000. Finally, Strive Financial Group LLC purchased a new position in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $52,000. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.